Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew Tutt

Showing results (51-60 of 91) with videos related to

Pageof 10
Sort By:
Lancet (London, England)|July 9, 2010
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trialM William Audeh, James Carmichael, Richard T Penson, et al.
Theranostics|July 27, 2017
Visualization of Tumor-Immune Interaction - Target-Specific Imaging of S100A8/A9 Reveals Pre-Metastatic Niche EstablishmentMichel Eisenblaetter, Fabian Flores-Borja, Jae Jin Lee, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 21, 2011
Challenges to the development of new agents for molecularly defined patient subsets: lessons from BRCA1/2-associated breast cancerSusan M Domchek, Gillian Mitchell, Geoffrey J Lindeman, et al.
Frontiers in Immunology|July 13, 2023
Serum-derived extracellular vesicles from breast cancer patients contribute to differential regulation of T-cell-mediated immune-escape mechanisms in breast cancer subtypesRosalind Graham, Patrycja Gazinska, Birong Zhang, et al.
The Journal of Molecular Diagnostics : JMD|February 20, 2009
A single-tube quantitative assay for mRNA levels of hormonal and growth factor receptors in breast cancer specimensAyuko A Iverson, Cheryl Gillett, Paul Cane, et al.
The New England Journal of Medicine|June 26, 2009
Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriersPeter C Fong, David S Boss, Timothy A Yap, et al.
Breast Cancer Research : BCR|October 15, 2017
Gene expression modules in primary breast cancers as risk factors for organotropic patterns of first metastatic spread: a case control studyKatherine Lawler, Efterpi Papouli, Cristina Naceur-Lombardelli, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 18, 2018
Repurposing Tin Mesoporphyrin as an Immune Checkpoint Inhibitor Shows Therapeutic Efficacy in Preclinical Models of CancerTamara Muliaditan, James W Opzoomer, Jonathan Caron, et al.
Annals of Surgical Oncology|December 24, 2011
Recommendations from an international consensus conference on the current status and future of neoadjuvant systemic therapy in primary breast cancerManfred Kaufmann, Gunter von Minckwitz, Elefhterios P Mamounas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 6, 2006
Late toxicity is not increased in BRCA1/BRCA2 mutation carriers undergoing breast radiotherapy in the United KingdomSusan Shanley, Kate McReynolds, Audrey Ardern-Jones, et al.
Pageof 10

Showing results (51-60 of 91) with videos related to

Sort By:
Pageof 10
Lancet (London, England)|July 9, 2010
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trialM William Audeh, James Carmichael, Richard T Penson, et al.
Theranostics|July 27, 2017
Visualization of Tumor-Immune Interaction - Target-Specific Imaging of S100A8/A9 Reveals Pre-Metastatic Niche EstablishmentMichel Eisenblaetter, Fabian Flores-Borja, Jae Jin Lee, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 21, 2011
Challenges to the development of new agents for molecularly defined patient subsets: lessons from BRCA1/2-associated breast cancerSusan M Domchek, Gillian Mitchell, Geoffrey J Lindeman, et al.
Frontiers in Immunology|July 13, 2023
Serum-derived extracellular vesicles from breast cancer patients contribute to differential regulation of T-cell-mediated immune-escape mechanisms in breast cancer subtypesRosalind Graham, Patrycja Gazinska, Birong Zhang, et al.
The Journal of Molecular Diagnostics : JMD|February 20, 2009
A single-tube quantitative assay for mRNA levels of hormonal and growth factor receptors in breast cancer specimensAyuko A Iverson, Cheryl Gillett, Paul Cane, et al.
The New England Journal of Medicine|June 26, 2009
Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriersPeter C Fong, David S Boss, Timothy A Yap, et al.
Breast Cancer Research : BCR|October 15, 2017
Gene expression modules in primary breast cancers as risk factors for organotropic patterns of first metastatic spread: a case control studyKatherine Lawler, Efterpi Papouli, Cristina Naceur-Lombardelli, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 18, 2018
Repurposing Tin Mesoporphyrin as an Immune Checkpoint Inhibitor Shows Therapeutic Efficacy in Preclinical Models of CancerTamara Muliaditan, James W Opzoomer, Jonathan Caron, et al.
Annals of Surgical Oncology|December 24, 2011
Recommendations from an international consensus conference on the current status and future of neoadjuvant systemic therapy in primary breast cancerManfred Kaufmann, Gunter von Minckwitz, Elefhterios P Mamounas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 6, 2006
Late toxicity is not increased in BRCA1/BRCA2 mutation carriers undergoing breast radiotherapy in the United KingdomSusan Shanley, Kate McReynolds, Audrey Ardern-Jones, et al.
Pageof 10